Ascelia Pharma

Ascelia Pharma is expected to release its Q3 2026 interim report on 5 November 2026. The following day at 11:00, CEO Magnus Corfitzen will present the results and provide an update on the company’s latest developments in a live online event.

Ascelia Pharma yesterday disclosed the findings from its 9 September Type A meeting with the FDA and discussed them at an investor call. The headline is that the FDA maintains its position that additional clinical evidence is required, but no longer presents a new clinical study with new patients as the only way to generate it.